Gagnon Securities LLC Decreases Stock Position in Standard BioTools Inc. (NASDAQ:LAB)

Gagnon Securities LLC trimmed its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB) by 60.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,930 shares of the company’s stock after selling 36,494 shares during the quarter. Gagnon Securities LLC’s holdings in Standard BioTools were worth $42,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Wolverine Trading LLC purchased a new stake in shares of Standard BioTools during the 3rd quarter valued at about $27,000. Nisa Investment Advisors LLC grew its holdings in Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares during the last quarter. Xponance Inc. bought a new position in Standard BioTools during the 2nd quarter valued at about $34,000. Creative Planning bought a new position in Standard BioTools during the 3rd quarter valued at about $39,000. Finally, Algert Global LLC bought a new position in Standard BioTools during the 2nd quarter valued at about $44,000. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Standard BioTools Trading Down 3.7 %

Shares of NASDAQ:LAB opened at $1.55 on Friday. The firm’s 50-day moving average is $1.82 and its 200 day moving average is $1.89. Standard BioTools Inc. has a 12 month low of $1.21 and a 12 month high of $3.04.

Analyst Upgrades and Downgrades

Separately, TD Cowen cut their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating on the stock in a report on Thursday, October 31st.

Standard BioTools Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.